Federal Circuit Rules for Pfizer in Suit Vs. Ranbaxy

Law360, New York (December 29, 2003, 12:00 AM EST) -- The Court of Appeals for the Federal Circuit last week upheld a preliminary injunction barring India’s Ranbaxy Pharmaceuticals from marketing a generic version of Pfizer's Vantin antibiotic, Pfizer said.

The court affirmed a lower court ruling by the U.S. District Court of New Jersey. In addition, it decided in Pfizer's favor on a cross-appeal of the amount of bond the company is obligated to post in the case. The determination of bond was remanded to the district court with instructions to reduce the $15 million it...
To view the full article, register now.